- Home
- ICCC vs XCUR Comparison
ICCC vs XCUR Comparison
Compare ICCC & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- XCUR
- Stock Information
- Founded
- ICCC 1982
- XCUR 2011
- Country
- ICCC United States
- XCUR United States
- Employees
- ICCC N/A
- XCUR N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- XCUR Health Care
- Exchange
- ICCC Nasdaq
- XCUR Nasdaq
- Market Cap
- ICCC 60.1M
- XCUR 59.0M
- IPO Year
- ICCC 1987
- XCUR N/A
- Fundamental
- Price
- ICCC $6.71
- XCUR $6.51
- Analyst Decision
- ICCC
- XCUR
- Analyst Count
- ICCC 0
- XCUR 0
- Target Price
- ICCC N/A
- XCUR N/A
- AVG Volume (30 Days)
- ICCC 41.8K
- XCUR 249.3K
- Earning Date
- ICCC 08-12-2025
- XCUR 08-12-2025
- Dividend Yield
- ICCC N/A
- XCUR N/A
- EPS Growth
- ICCC N/A
- XCUR N/A
- EPS
- ICCC N/A
- XCUR N/A
- Revenue
- ICCC $27,302,766.00
- XCUR N/A
- Revenue This Year
- ICCC N/A
- XCUR N/A
- Revenue Next Year
- ICCC N/A
- XCUR N/A
- P/E Ratio
- ICCC N/A
- XCUR N/A
- Revenue Growth
- ICCC 28.29
- XCUR N/A
- 52 Week Low
- ICCC $3.34
- XCUR $1.44
- 52 Week High
- ICCC $7.60
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- ICCC 49.68
- XCUR 41.01
- Support Level
- ICCC $5.63
- XCUR $5.05
- Resistance Level
- ICCC $7.14
- XCUR $8.36
- Average True Range (ATR)
- ICCC 0.64
- XCUR 1.00
- MACD
- ICCC -0.06
- XCUR -0.03
- Stochastic Oscillator
- ICCC 42.58
- XCUR 44.29
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.